Brief: HUTCHMED (China) Says Regulatory Filings For Orpathys Plus Tagrisso Accepted For Review In Europe And Japan
Mon 01:19
BRIEF-HUTCHMED (China) Says Regulatory Filings For Orpathys Plus Tagrisso Accepted For Review In Europe And Japan Nov 2 (Reuters) - HUTCHMED (China) Ltd 0013.HK:
REGULATORY FILINGS FOR ORPATHYS PLUS TAGRISSO ACCEPTED FOR REVIEW IN EUROPE AND JAPAN
EMA VALIDATES AND ACCEPTS MAA FOR ORPATHYS PLUS TAGRISSO IN NSCLC
Further company coverage: 0013.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on HUTCHMED (China)
See all newsSovleplenib Granted FDA Orphan Drug Designation
Brief: Hutchmed (China) Says FDA Grants Orphan Drug Designation To Sovleplenib For Autoimmune Hemolytic Anemia
Regulatory Filings Accepted for Review
Brief: HUTCHMED (China) Says Regulatory Filings For Orpathys Plus Tagrisso Accepted For Review In Europe And Japan
US FDA Grants Sovleplenib Orphan Drug Designation